GenBio Announces Provisional Patent for Inflamoxil, a Next-Generation Anti-Inflammatory Therapy

GenBio Inc.

New Trademark Inflamoxil

Provisional Patent Application Filed With USPTO

Next-generation therapy aims to redefine treatment for inflammatory conditions

ALISO VIEJO, CA, UNITED STATES, September 4, 2025 /EINPresswire.com/ -- GenBio, a biotechnology company focused on advancing novel therapies for chronic inflammation, today announced the filing of a provisional patent for its latest research innovation, Inflamoxil. This milestone reflects the Company’s continued progress in developing safe and effective next-generation treatment modalities that target the underlying mechanisms of chronic inflammation.

Chronic inflammation remains a significant unmet medical need, with patients and healthcare providers urgently seeking new solutions. Inflamoxil is designed to fill this gap by leveraging specific novel extracts and compounds identified through GenBio’s rigorous research and selection process. These compounds demonstrate both safety and efficacy, aligning with GenBio’s high standards for therapeutic development.

A key differentiator for GenBio is its unique ability to identify and target multiple biomarkers simultaneously. This capability positions the Company to address a broad range of inflammatory ailments across multiple market segments. In particular, Inflamoxil aims to block pro-inflammatory cytokines, a critical driver of chronic inflammation. GenBio is also exploring the compound’s potential to enhance the effectiveness of conventional antibiotics by mitigating antibiotic resistance mechanisms—an approach that could have a far-reaching impact on global health.

About GenBio

GenBio is a biotechnology company dedicated to pioneering next-generation therapies that address the root causes of chronic inflammation and related conditions. By combining advanced biomarker identification with innovative therapeutic strategies, GenBio is committed to delivering safe, effective, and transformative treatments that address urgent unmet medical needs across multiple markets.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements regarding GenBio’s research, development efforts, and future product candidates, including Inflamoxil. These statements are based on current expectations, projections, and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially. Forward-looking statements include, but are not limited to, statements regarding potential therapeutic benefits, market opportunities, and development timelines. GenBio undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Todd D. Sonoga
GenBio Inc.
+1 9497058021
email us here
Visit us on social media:
LinkedIn
Facebook
X
Other

GenBio Inc Elevator Pitch

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.